
    
      Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can
      be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125
      mg three times per day orally for 8 weeks as neoadjuvant therapy; then they receive surgical
      resection of the tumor. If there is curative effect of Icotinib according to the RECIST or
      pathological report, the patients will continue receive Icotinib for two years as adjuvant
      therapy after surgery or till progressive disease or unaccepted toxicity. The primary
      objective of this study is evaluate the pulmonary and metastases lesions objective response
      rate after Icotinib preoperative therapy.
    
  